Nomogram for Prediction of fatal outcome in Patients with Severe COVID-19: A Multicenter Study

Yun Yang  
The Third Affiliated Hospital of the Second Military Medical University

Xiaofei Zhu  
The First Affiliated Hospital of the Second Military Medical University

Jian Huang  
The Third Affiliated Hospital of the Second Military Medical University

Cui Chen  
The Third Affiliated Hospital of the Second Military Medical University

Yang Zheng  
904 Hospital of PLA Joint Logistic Support Force

Wei He  
924 Hospital of PLA Joint Logistic Support Force

Linghao Zhao  
The Third Affiliated Hospital of the Second Military Medical University

Qian Gao  
The Third Affiliated Hospital of the Second Military Medical University

Xuanxuan Huang  
The Third Affiliated Hospital of the Second Military Medical University

Lijuan Fu  
The Third Affiliated Hospital of the Second Military Medical University

Yu Zhang  
The Third Affiliated Hospital of the Second Military Medical University

Yanqin Chang  
The Third Affiliated Hospital of the Second Military Medical University

Huojun Zhang  
The First Affiliated Hospital of the Second Military Medical University

Zhijie Lu (✉ luzhijieehbh@126.com)  
Second Military Medical University

Research

Keywords: Severe COVID-19, Nomogram, Prediction, Survival
Abstract

**Background & Aims:** To develop an effective model of predicting fatal outcome in the severe coronavirus disease 2019 (COVID-19) patients.

**Methods:** Between February 20, 2020 and April 4, 2020, consecutive COVID-19 patients from three designated hospitals were enrolled in this study. Independent high-risk factors associated with death were analyzed using Cox proportional hazard model. A prognostic nomogram was constructed to predict the survival of severe COVID-19 patients.

**Results:** There were 124 severe patients in the training cohort, and there were 71 and 76 severe patients in the two independent validation cohorts, respectively. Multivariate Cox analysis indicated that age ≥ 70 years (HR 1.184, 95% CI 1.061-1.321), Panting (breathing rate ≥ 30/min) (HR 3.300, 95% CI 2.509-6.286), lymphocyte count < 1.0 × 10^9/L (HR 2.283, 95% CI 1.779-3.267), and IL-6 >10pg/mL (HR 3.029, 95% CI 1.567-7.116) were independent high-risk factors associated with fatal outcome. We developed the nomogram for identifying survival of severe COVID-19 patients in the training cohort (AUC 0.900, [95% CI 0.841-0.960], sensitivity 95.5%, specificity 77.5%); in validation cohort 1 (AUC 0.811, [95% CI 0.763-0.961], sensitivity 77.3%, specificity 73.5); in validation cohort 2 (AUC 0.862, [95% CI 0.698-0.924], sensitivity 92.9%, specificity 64.5%). The calibration curve for probability of death indicated a good consistence between prediction by the nomogram and the actual observation. The prognosis of severe COVID-19 patients with high levels of interleukin-6 (IL-6) receiving tocilizumab was better than that of those patients without tocilizumab both in the training and validation cohorts, but without difference (p = 0.105 for training cohort, p = 0.133 for validation cohort 1, and p = 0.210 for validation cohort 2).

**Conclusions:** This nomogram could help clinicians to identify severe patients who have high risk of death, and to develop more appropriate treatment strategies to reduce the mortality of severe patients. Tocilizumab may improve the prognosis of severe COVID-19 patients with high levels of IL-6.

Introduction

The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is a new pneumonia that has spread rapidly throughout the world [1]. Because of the rapid transmission spread of COVID-19, the number of new cases and death is increasing. COVID-19 has become a major public health crisis [1].

Previous studies have indicated that in all COVID-19 patients, the incidence of severe cases is approximately 15% [2,3]. The mortality rate of severe COVID-19 patients varies from 8% to 61.5% and significantly increases among older patients [4-9]. Early medical intervention is very important to reduce the mortality of severe patients. Thus, it is of great importance to screen out severe patients with a high risk of death promptly and accurately at the initial admission [10]. However, this is particularly difficult because of limited medical resources and staff and the large number of patients. Therefore, elucidating
the independent risk factors and establishing an accurate model for predicting severe COVID-19 patients at high risk of death is necessary. A previously established nomogram suggested five prognostic factors for predicting the outcome: APACHE II, CK, CRP, IgA, and the interaction between CK and APACHE II[11]. However, risk factors associated with fatal outcomes in severe patients are unclear. This study aimed to provide a model to help clinicians identify patients with severe COVID-19 at high risk of death, which may be beneficial for decision making regarding treatment strategies.

**Patients And Methods**

**Study population**

Between February 20, 2020 and April 4, 2020, consecutive confirmed COVID-19 patients were assessed to enter into this study from three designated hospitals of COVID-19 in China: the Guanggu Branch of the Women and Children's Hospital of Hubei Province, Tongji TaiKang Hospital and Huoshen Mountain Hospital. The diagnosis of COVID-19 was based on the WHO interim guidance and guidelines for diagnosis and treatment of novel coronavirus pneumonia (5th version) released by National Health Commission of China [12,13]. The presence of SARS-CoV-2 in respiratory specimens was confirmed by a positive result of quantitative real-time reverse transcriptase-polymerase-chain-reaction (qRT-PCR) assay from nasal or pharyngeal swab specimens. Swab samples were collected and tested for SARS-CoV-2 with the Chinese Center for Disease Control and Prevention (CDC) recommended Kit (BioGerm, Shanghai, China), following WHO guidelines for qRT-PCR [14-16]. All samples were tested for SARS-CoV-2 by use of qRT-PCR with the CDC recommended Kit. The test results were confirmed by nested RT-PCR with designed primers. The nested RT-PCR assay was performed according to previous report [17].

Severe COVID-19 group was defined if meeting at least one of the following criteria:(1) Shortness of breath, breathing rate $\geq 30$/min, (2) Arterial oxygen saturation ($\text{SaO}_2$, Resting status) $\leq 93\%$, or (3) the ratio of partial pressure of arterial oxygen ($\text{PaO}_2$) to fraction of inspired oxygen ($\text{FiO}_2$) $\leq 300\text{mmHg}$.

During the study period, a total of 2541 patients were enrolled into this study. Of 2541 cases included in this study, 1056 patients were from Guanggu Branch of the Women and Children's Hospital of Hubei Province, 726 were from Tongji TaiKang Hospital, and 759 were from Huoshen Mountain Hospital. According to the definition of severe COVID-19 described above, there were 124, 71, and 76 severe cases from the three hospitals, respectively. Therefore, 124 patients with severe diseases from Guanggu Branch of the Women and Children's Hospital of Hubei Province were included in the training cohort, while 71 and 76 severe cases in other two hospitals formed validation cohort. The selection of the study population was shown in Supplemental Figure. 1. The study was approved by the Ethics Committee of all centers. Written informed consent was waived by the Ethics Commission of each hospital for emerging infections.

**Data Collection**
All patients received chest computed tomography (CT) and serological examinations at admission. Laboratory tests included routine blood tests, liver function, renal function, coagulation profile, C-reactive protein (CRP), procalcitonin (PCT), interleukin-6 (IL-6), and arterial blood gas. The oxygen saturation (SaO\textsubscript{2}) was measured using pulse oxygen saturation in room air at resting status. Comorbidity was defined as having at least one of the followings: hypertension, diabetes, cardiovascular disease, cerebrovascular disease, chronic lung disease, and malignant tumor for at least 6 months. All data were collected, re-checked for accuracy independently by at least two researchers.

**Statistical analysis**

Continuous variables were expressed as mean (SD). Categorical variables were expressed as frequency (percentage). Categorical variables were compared by the \(\chi^2\) test or Fisher's exact test. Continuous variables were compared by the Student's t test or Mann–Whitney U test. Survival curves were analyzed using the Kaplan-Meier method. Differences between curves were assessed using the log-rank test.

Univariate and multivariate COX proportional regression analysis was used for investigating the independent risk factors of death. The independent risk factors associated with the risk of mortality of patients with severe COVID-19 were used to build the nomogram in the training cohort. The performance and accuracy of the established nomogram was assessed by receiver operating characteristic (ROC) curve and calibration with 1000 bootstrap samples. The area under ROC (AUC) and optimal cut-off values were determined. Decision curve analysis (DCA) based on the net benefit was depicted by the package of rmdain R. The nomogram was validated in the validation cohorts 1 and 2, respectively. The nomogram was constructed and evaluated using the R software version 3.4.1 package with the rms and hmisc. All statistical analysis was performed using R version 3.4.1, a \(p<0.05\) in two-tailed was the significance threshold.

**Results**

**Patient clinical characteristics**

Of 2541 patients included in this study, 271 patients had severe COVID-19 and 2270 were non-severe cases. Supplemental Table 1 indicated the basic characteristics of the study cohorts. Compared with non-severe cases, patients were older \((p < 0.001)\) and more males \((p < 0.001)\) were found in the severe disease cohort. In addition, there were more comorbidities and smokers in severe cases \((p < 0.001)\). The proportion of patients with panting was higher significantly in the severe cases \((p < 0.001)\). Significantly higher levels of white blood cell (WBC) count, neutrophil count, CRP, PCT, IL-6, total bilirubin (TBIL), alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), \(\gamma\)-glutamyl transpeptidase (\(\gamma\)-GT), and creatinine (Cre) were identified in severe cases \((p < 0.001)\), while the levels of lymphocyte count, platelet (PLT), and oxygen saturation (SaO2) of patients with severe diseases were significantly lower than those of non-severe ones \((p < 0.001)\). There were 186 patients with no manifestations of chest CT in non-severe COVID-19 cohort, and no significant differences of the findings
of chest CT between severe and non-severe cases were found \( (p > 0.05) \). By the end of April 4, 2020, there were 58 and 39 patients died in the severe and non-severe disease group, respectively. (Supplemental Table 1).

The basic characteristics of the severe patients are listed in Supplemental Table 2. The median age of the patients was 68 (range 20 – 100) years. One hundred and fifty-two (56.09%) patients were males and there were one hundred nineteen (43.91%) female patients. There were 73 (26.94%) patients who had a high white blood cell (WBC) count of \( >10 \times 10^9/L \), and 148 patients (54.61%) with lymphopenia defined as lymphocyte count of \( \leq 1.0 \times 10^9/L \). Ninety-five (35.06%) patients had a high neutrophil count of \( >6.3 \times 10^9/L \), while 26 (9.59%) patients had a low platelet (PLT) count of \( <100 \times 10^9/L \). Ground-glass opacity and consolidation was found in 122 (45.02%) and 114 (42.07%) patients, respectively. In addition, Twenty-eight (10.33%) and seven (2.58%) patients had thickened interlobular septa and nodular lesions, respectively in chest CT. Of 271 severe patients, there were 58 patients died during the study period (Supplemental Table 2).

Comparison of baseline characteristics between patients in training and validation cohorts can be seen in Table 1. There were significant differences of the age, proportion of smokers, incidence of panting, white blood cell count (WBC), neutrophil count, CRP and SaO\(_2\) at admission between the three cohorts \( (p < 0.05) \). There was no significant difference in the other variables between the three cohorts \( (p > 0.05) \). By the end of April 4, 2020, 22 severe COVID-19 patients died in the training group, and 22 and 14 patients died in the validation group 1 and validation group 2, respectively (Table 1).

The baseline characteristics of patients in the training cohort were shown in Table 2. There were no significant differences in gender, TB, ALT, AST, LDH, \( \gamma \)-GT, Cre, PLT, and the proportion of smoker between survivors and non-survivors \( (p > 0.05) \). Survivors were significantly younger than the non-survivors in the training cohort \( (p < 0.05) \), however, the proportion of patients with multiple comorbidity and panting (breathing rate \( \geq 30/\text{min} \)) was significantly higher in non-survivors \( (p < 0.05) \). In addition, WBC and neutrophil count, CRP, D-dimer, PCT, and IL-6 was also significantly higher in non-survivors \( (p < 0.05) \). The lymphocyte count was significantly lower in non-survivors \( (p < 0.05) \).

**Independent High-risk Factors Associated with the Fatal Outcome**

All variables listed in Table 1 were analyzed by univariate and multivariate Cox regression analysis. Multivariate Cox analysis indicated that age \( \geq 70 \) years (HR 1.184, 95% CI 1.061-1.321), Panting(breathing rate \( \geq 30/\text{min} \)) (HR 3.300, 95% CI 2.509-6.286), lymphocyte count \( < 1.0 \times 10^9/L \) (HR 2.283, 95% CI 1.779-3.267), and IL-6 \( >10\text{pg/mL} \) (HR 3.029, 95% CI 1.567-7.116) were independent risk factors associated with fatal outcomes (Table 3).

**Survival Analysis in the Patients with High Level of IL-6**

Due to high level of IL-6 correlating with poor outcomes in severe COVID-19 patients, the therapeutic effect of tocilizumab in the patients with high IL-6 was further analyzed. In the training cohort, it was
demonstrated that the prognosis of patients receiving tocilizumab was better than that of patients not receiving tocilizumab, but without significance \((p = 0.105)\) (Supplemental Figure.2A). Similar results were also observed in the validation cohort 1 and validation cohort 2, respectively \((p = 0.133, p = 0.210)\) (Supplemental Figure.2B-C).

**Construction and validation of the nomogram**

Four independent risk factors found to be associated with the risk of mortality of patients in the multivariate analyses were incorporated into the nomogram (Figure.1). The ROC curve was employed to assess the predictive ability of the established nomogram, and the result demonstrated that the AUC was 0.900 (95% CI: 0.841-0.960) in the taring cohort, with a sensitivity of 95.5% and specificity of 77.5% (Figure. 2A). Moreover, the calibration curves for nomogram predicted mortality indicated that a good consistency between observed actual outcomes and predicted ones in the training cohort (Figure.3A).

In the validation cohort 1, the AUC was 0.811 (95%CI: 0.763-0.961) for patients with a sensitivity of 77.3% and specificity of 73.5% (Figure. 2B). In the validation cohort 2, the AUC was 0.862 (95%CI: 0.698-0.924) for patients with a sensitivity of 92.9% and specificity of 64.5% (Figure. 2C). The calibration curves also showed good agreement between prediction and observation in the risk of mortality in the two validation cohorts (Figure.3B-C).

**Clinical application of the nomogram**

DCA based on the net benefit and threshold probabilities was performed to assess the clinical applicability of the risk prediction nomogram. The DCA showed that our risk prediction nomogram had a superior net benefit with a wide range of threshold probabilities in the training cohort and validation cohorts (Figure. 4A-C).

**Discussion**

Previous studies have shown that the mortality rate of severe COVID-19 patients was significantly higher than that of mild patients \([6,18]\). Therefore, a reduction in the mortality of severe patients is pivotal in the case of treatment. Our study revealed the clinical characteristics and risk factors for fatal outcomes in confirmed severe COVID-19 patients based on multicenter cohorts.

Multivariate Cox analysis in this study indicated that age, lymphopenia, respiratory rate \(\geq 30/\text{min}\), and IL-6 were independent high-risk factors associated with poor prognosis. Older age has been proven to be a risk factor for survival in many previous studies \([19-22]\). Elderly patients with severe COVID-19 were more likely to develop fatal outcomes because of the rapid progression of the disease, which reminded us of providing early intervention for elderly severe patients. Similarly, lymphopenia was more common in the nonsurvivors and severe cases according to previous reports, suggesting dysregulation of the immune response in patients with COVID-19 \([23-25]\). Nevertheless, most of these were only descriptive studies. A study clarified that lower lymphocyte counts were predictive of COVID-19 progression \([26]\), whereas the
impact of lymphocyte counts on the survival of severe COVID-19 was unclear. This study demonstrated that a lymphocyte count $< 1.0 \times 10^9$/L was independently associated with death in severe cases.

Recent studies have found that the cytokine storm is an important factor leading to rapid disease progression and poor prognosis [27,28]. IL-6 is one of the major cytokines involved in cytokine storms [29,30]. A previous univariate analysis showed that the IL-6 level was associated with worse survival without significance [20]. Our study showed that a high level of IL-6 was a predictor of death in severe COVID-19 patients. Additionally, the survival curve showed that the outcome was better in patients with tocilizumab than in patients without tocilizumab in the training cohort. Nonetheless, no significant difference was found. Similar results were also found in validation cohort 1 and validation cohort 2. The reason for this result may be attributable to the small sample size. The effect of tocilizumab on the survival of patients with severe COVID-19 needs further investigation in larger cohorts.

Increasing respiratory rate is an important clinical feature of acute respiratory distress syndrome (ARDS), which is a major cause of death in severe COVID-19 patients [9,19,31]. A previous study showed that a respiratory rate $\geq 24$/min was a risk factor for death in the univariate analysis [20], whereas no significance was found after the multivariate regression analysis. Our multivariate regression analysis clarified that a respiratory rate $\geq 30$/min was a predictor of death. For patients with increasing respiratory rates, especially those with respiratory rate $\geq 30$/min, it is necessary for physicians to be aware of the potential progression of ARDS.

Many previous studies have shown that comorbidity was significantly associated with high mortality rate and disease progression [26,32]. Nevertheless, in this study, the significance of comorbidity was only indicated in the univariate analysis, but not in the multivariate regression analysis, which may be ascribed to different patients enrolled in these studies. All the patients included in this study had severe COVID-19, and the proportion of comorbidities was approximately 70%, which was significantly higher than those in other studies.

Previous studies have shown several prediction models with different parameters [2,26,32,33]. Compared with other studies, the predictive effect of age, panting, and lymphopenia has been described in previous reports, while the main feature of this study is the analysis of the prognostic value of IL-6 in severe COVID-19 patients for the first time. IL-6 plays an important role in the pathophysiological changes of severe cases. However, the prediction value of IL-6 was not shown in other prediction models. In addition, our study also indicated that tocilizumab, a monoclonal antibody against the IL-6 receptor, may improve the prognosis of severe COVID-19 patients with high levels of IL-6.

Our study has some limitations. First, this is a retrospective study, and there may be potential biases in the selection of patients. Second, the sample size of the study was relatively small, and the results need to be further validated in a larger cohort.

**Conclusion**
This study firstly developed a nomogram for predicting fatal outcomes in the severe COVID-19 patients. The four predictors included in the model are easy to obtain. The prediction risk of the model indicated a good consistence with the observed one. Hence, this nomogram may be conducive to more effective treatment to reduce the mortality of those severe cases at high risk of death.

**Declarations**

**Acknowledgements**

We would like to thank the staff of the Department of Critical Care Medicine of Huoshen Mountain Hospital, Wuhan Hubei Province, who contributed to this study by collecting the required data in the hospital data system.

**Authors’ contributions**

Both Drs. Yun Yang, Xiaofei Zhu, Jian Huang, and Cui Chen designed this study. Drs. Yang Zheng, Wei He, Linghao Zhao, Qian Gao, Xuanxuan Huang, Lijuan Fu, Yu Zhang, and Yanqin Chang collected the data. Drs. Yun Yang and Jian Huang were responsible for the statistical analysis. Dr. Yun Yang wrote the draft. Drs. Xiaofei Zhu, Yanqin Chang, and Huojun Zhang revised this draft. Dr. Zhijie Lu finalized this manuscript. All the authors approved the final version of this manuscript.

**Funding**

This work was supported by grants from National Natural Science Foundation of China (81502416) to Dr. Yun Yang.

**Availability of data and materials**

The patient level data has been uploaded to the Figshare database. Dataset. http://doi.org/10.6084/m9.figshare.12866060.v1.

**Ethics approval and consent to participate**

The study was approved by the Ethics Committee of all the study centers. Written informed consent was waived by the Ethics Commission of each hospital for emerging infectious.

**Consent for publication**

No individual participant data is reported that would require consent to publish from the participant (or legal parent or guardian for children).

**Competing interests**
The authors declare that they have no competing interests

**Author details**

1 The Third Affiliated Hospital of Navy Medical University; Second Military Medical University, Shanghai 200438, China; 2 The First Affiliated Hospital of Second Military Medical University, Shanghai 200438, China; 3 Guanggu branch of Hubei maternal and Child Health Hospital, Wuhan 430070, China; 4 904 Hospital of PLA Joint Logistic Support Force, Wuxi 215000, China; 5 Tongji TaiKang Hospital, Wuhan 430050, China; 6 924 Hospital of PLA Joint Logistic Support Force, Guilin 541002, China; 7 Huoshen Mountain Hospital, Wuhan 430113, China

**Abbreviations**

COVID-19, coronavirus disease 2019; SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2; qRT-PCR, quantitative real-time reverse transcriptase-polymerase-chain-reaction; CT, computed tomography; WBC, white blood cell; PLT, platelet; CRP, C-reactive protein; PCT, procalcitonin; IL-6, interleukin-6; SaO₂, Oxygen saturation; TBIL, total bilirubin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; LDH, lactate dehydrogenase; γ-GT, γ-glutamyl transpeptidase; Cre, creatinine; HR, hazard ratio; 95% CI, 95% Confidence interval; ARDS, acute respiratory distress syndrome.

**References**

1. World Health Organization. Coronavirus disease 2019 (COVID-19) situation report-72. Published April 1st, 2020. Accessed April 1, 2020. [https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200401-sitrep-72-covid-19.pdf?sfvrsn=3dd8971b_2](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200401-sitrep-72-covid-19.pdf?sfvrsn=3dd8971b_2).

2. Gong J, Ou J, Qiu X, Jie YS, Chen YQ, Yuan LX, et al. A Tool to Early Predict Severe Corona Virus Disease 2019 (COVID-19) : A Multicenter Study using the Risk Nomogram in Wuhan and Guangdong, China. Clin Infect Dis. 2020; 71(15):833-840.

3. Guan WJ, Ni ZY, Hu Y, Liang WH, Qu CQ, He JX, et al. Clinical characteristics of 2019 novel coronavirus infection in China. medRxiv 2020.02.06.20020974.

4. Wang DW, Hu B, Hu C, Zhu FF, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020; 323(11):1061-1069.

5. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020; 382(18):1708-1720.

6. Chen NS, Zhou M, Dong X, Qu JM, Gong FY, Yang H, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395(10223):507-513.

7. Huang CL, Wang YM, Li XW, Ren LL, Zhao JP, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223):497-506.
8. Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, RJerome K, Nalla AK, et al. Covid-19 in Critically Ill Patients in the Seattle Region - Case Series. N Engl J Med. 2020; 382(21):2012-2022.

9. Yang XB, Yu Y, Xu JQ, Shu HQ, Xia JA, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020; 8(5):475-481.

10. Zhang GM, Zhang J, Wang BW, Zhu XL, Wang Q, Qiu SM, et al. Analysis of clinical characteristics and laboratory findings of 95 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a retrospective analysis. Respir Res. 2020; 21(1):74.

11. Xie JJ, Shi D, Bao MY, Bao MY, Hu XY, Wu WR, et al. A Predictive Nomogram for Predicting Improved Clinical Outcome Probability in Patients with COVID-19 in Zhejiang Province, China. Engineering (Beijing). 2020 Jun 6; Doi: 10.1016/j.eng.2020.05.014.

12. World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected: interim guidance. [Published January 28, 2020]. Accessed January 31, 2020. https://www.who.int/publications-detail/clinical-managementof-severe-acute-respiratory-infection-when-novelcoronavirus-(ncov)-infection-is-suspected.

13. National Health Commission (NHC) of the PRC and National Administration of Traditional Chinese Medicine of the PRC. Guidance for Corona Virus Disease 2019: Prevention, Control, Diagnosis and Management. Peoples Medical Publishing House. 2020.

14. WHO. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. Interim guidance. Jan 12, 2020. https://www.who.int/docs/default-source/coronaviruse/clinical-management-of-novel-cov.pdf (accessed Feb 4, 2020).

15. WHO. Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases. Interim guidance. Jan 17, 2020. https://www.who.int/publications-detail/laboratory-testing-for-2019-novel-coronavirus-in-suspected-human-cases-20200117 (accessed Feb 4, 2020).

16. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020; 25(3):2000045.

17. Chen HJ, Guo JJ, Wang C, Luo F, Yu XC, Zhang W, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet. 2020; 395(10226):809-815.

18. Yang Y, Lu Q, Liu M, Wang YX, Zhang AR, Jalali N, et al. Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China. medRxiv 2020: 2020.02.10.20021675.

19. Chen T, Wu D, Chen H, Yan WM, Yang DL, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020; 368:m1091.

20. Zhou F, Yu T, Du R, Fan GH, Liu Y, Liu ZB, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229):1054-1062.

21. Team CC-R. Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) - United States, February 12-March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020; 69(12):343-346.
22. Li LZ, Zhang BH, He B, Gong ZJ, Chen XB. Critical patients with coronavirus disease 2019: Risk factors and outcome nomogram. J Infect. 2020; 80(6):e37-e38.

23. Wang F, Nie JY, Wang HZ, Zhao Q, Xiong Y, Deng LP, et al. Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia. J Infect Dis. 2020; 221(11):1762-1769.

24. Qin C, Zhou LQ, Hu ZW, Zhang SQ, Yang S, Tao Y, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020; 71(15):762-768.

25. Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, Politou M, et al. Hematological findings and complications of COVID-19. Am J Hematol. 2020; 95(7):834-847.

26. Dong J, Zhang DW, Xu J, Chen Z, Yang TN, Zhao P. Prediction for Progression Risk in Patients with COVID-19 Pneumonia: the CALL Score. Clin Infect Dis. 2020; Sep 12;71(6):1393-1399.

27. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the 'Cytokine Storm' in COVID-19. J Infect. 2020; 80(6):607-613.

28. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020; 395(10229):1033-1034.

29. Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents. 2020; 55(5):105954.

30. Zhang S, Li L, Shen AZ, Chen YW, Qi ZQ. Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia. Clin Drug Investig. 2020; 40(6):511-518.

31. Yang F, Shi SB, Zhu JL, Shi LZ, Dai K, Chen XB, et al. Analysis of 92 deceased patients with COVID-19. J Med Virol. 2020; 10.1002.

32. Chen RC, Liang WH, Jiang M, Guan WJ, Zhan C, Wang T, et al. Risk factors of fatal outcome in hospitalized subjects with coronavirus disease 2019 from a nationwide analysis in China. Chest. 2020; 158(1):97-105.

33. Zhang S, Guo MF, Duan LM, Wu F, Hu GR, Wang ZH, et al. Development and validation of a risk factor-based system to predict short-term survival in adult hospitalized patients with COVID-19: a multicenter, retrospective, cohort study. Crit Care. 2020; 24(1):438.

Tables

Table 1. Comparison of Baseline characteristics between patients in Training and Validation Cohorts
| Variables                  | Training Cohort (N=124) | Validation Cohort 1 (N=71) | Validation Cohort 2 (N=76) | P   |
|----------------------------|-------------------------|-----------------------------|----------------------------|-----|
|                            | N (%)                   | N (%)                       | N (%)                       |     |
| **Age**                    |                         |                             |                             | 0.001 |
| ≥70 years                  | 73 (58.87)              | 25 (35.21)                  | 29 (38.16)                  |     |
| <70 years                  | 51 (41.13)              | 46 (64.79)                  | 47 (61.84)                  |     |
| **Gender**                 |                         |                             |                             | 0.810 |
| Male                       | 69 (55.65)              | 42 (59.15)                  | 41 (53.95)                  |     |
| **Comorbidity**            |                         |                             |                             | 0.291 |
| Without comorbidity        | 31 (25.00)              | 27 (38.03)                  | 26 (34.21)                  |     |
| With single comorbidity    | 38 (30.65)              | 16 (22.54)                  | 21 (27.63)                  |     |
| With multiple comorbidity  | 55 (44.35)              | 28 (39.43)                  | 29 (38.16)                  |     |
| **Smoke**                  |                         |                             |                             | <0.001 |
| 66 (53.23)                 | 16 (22.54)              | 19 (25.00)                  |                             |     |
| Panting (breathing rate ≥ 30/min) | 56 (45.16)          | 63 (88.73)                  | 67 (88.16)                  | <0.001 |
| **WBC**                    |                         |                             |                             | 0.005 |
| >10*10^9/L                 | 24 (19.35)              | 29 (40.85)                  | 20 (26.32)                  |     |
| ≤10*10^9/L                 | 100 (80.65)             | 42 (59.15)                  | 56 (73.68)                  |     |
| **Lymphocyte**             |                         |                             |                             | 0.352 |
| >1.0*10^9/L                | 56 (45.16)              | 28 (39.44)                  | 39 (51.32)                  |     |
| ≤1.0*10^9/L                | 68 (54.84)              | 43 (60.56)                  | 37 (48.68)                  |     |
| **Neutrophil**             |                         |                             |                             | 0.013 |
| >6.3*10^9/L                | 36 (29.03)              | 35 (49.30)                  | 24 (31.58)                  |     |
| ≤6.3*10^9/L                | 88 (70.97)              | 36 (50.70)                  | 52 (68.42)                  |     |
| **PLT**                    |                         |                             |                             | 0.346 |
| ≥100*10^9/L                | 114 (91.94)             | 61 (85.92)                  | 70 (92.11)                  |     |
| <100*10^9/L                | 10 (8.06)               | 10 (14.08)                  | 6 (7.89)                    |     |
| **CRP**                    |                         |                             |                             | 0.026 |
|                | >10mg/L | ≤10mg/L | D-dimer | >0.55mg/L | ≤0.55mg/L | PCT | >0.05ng/mL | ≤0.05ng/mL | IL-6 | SaO₂ on admission | >90% | <90% | TBIL | >20umol/L | ≤20umol/L | ALT | ≥40U/L | <40U/L | AST | ≥40U/L | <40U/L | LDH | ≥245U/L | <245U/L | γ-GT | ≥50U/L | <50U/L |
|----------------|---------|---------|---------|-----------|-----------|-----|-----------|-----------|------|-----------------|-------|------|------|-----------|-----------|-----|--------|--------|-----|--------|--------|-----|--------|--------|-----|--------|--------|
| ≥10pg/mL       | 70(56.45)| 36(50.70)|        | 28(36.84) |            |     |           |           |      |                 |       |      |      |           |           |     |        |        |     |        |        |     |        |        |
| ≤10pg/mL       | 54(43.55)| 35(49.30)|        | 48(63.16) |            |     |           |           |      |                 |       |      |      |           |           |     |        |        |     |        |        |     |        |        |
| D-dimer        |         |         | 0.992   |           |           |     |           |           |      |                 |       |      |      |           |           |     |        |        |     |        |        |     |        |        |
| >0.55mg/L      | 81(65.32)| 46(64.79)|        | 50(65.79) |            |     |           |           |      |                 |       |      |      |           |           |     |        |        |     |        |        |     |        |        |
| ≤0.55mg/L      | 43(34.68)| 25(35.21)|        | 26(34.21) |            |     |           |           |      |                 |       |      |      |           |           |     |        |        |     |        |        |     |        |        |
| PCT            |         |         | 0.312   |           |           |     |           |           |      |                 |       |      |      |           |           |     |        |        |     |        |        |     |        |        |
| >0.05ng/mL     | 87(70.16)| 57(80.28)|        | 56(73.68) |            |     |           |           |      |                 |       |      |      |           |           |     |        |        |     |        |        |     |        |        |
| ≤0.05ng/mL     | 37(29.84)| 14(19.72)|        | 20(26.31) |            |     |           |           |      |                 |       |      |      |           |           |     |        |        |     |        |        |     |        |        |
| IL-6           |         |         | 0.298   |           |           |     |           |           |      |                 |       |      |      |           |           |     |        |        |     |        |        |     |        |        |
| ≥10pg/mL       | 68(54.83)| 47(66.20)|        | 44(57.89) |            |     |           |           |      |                 |       |      |      |           |           |     |        |        |     |        |        |     |        |        |
| <10pg/mL       | 56(45.17)| 24(33.80)|        | 32(42.11) |            |     |           |           |      |                 |       |      |      |           |           |     |        |        |     |        |        |     |        |        |
| SaO₂ on admission | <0.001 |           |         |           |           |     |           |           |      |                 |       |      |      |           |           |     |        |        |     |        |        |     |        |        |
| ≥90%           | 85(68.55)| 18(25.35)|        | 34(44.74) |            |     |           |           |      |                 |       |      |      |           |           |     |        |        |     |        |        |     |        |        |
| <90%           | 39(31.45)| 53(74.65)|        | 42(55.26) |            |     |           |           |      |                 |       |      |      |           |           |     |        |        |     |        |        |     |        |        |
| TBIL           |         |         | 0.098   |           |           |     |           |           |      |                 |       |      |      |           |           |     |        |        |     |        |        |     |        |        |
| ≥20umol/L      | 45(36.29)| 16(22.53)|        | 28(36.84) |            |     |           |           |      |                 |       |      |      |           |           |     |        |        |     |        |        |     |        |        |
| <20umol/L      | 79(63.71)| 55(77.47)|        | 48(63.16) |            |     |           |           |      |                 |       |      |      |           |           |     |        |        |     |        |        |     |        |        |
| ALT            |         |         | 0.363   |           |           |     |           |           |      |                 |       |      |      |           |           |     |        |        |     |        |        |     |        |        |
| ≥40U/L         | 35(28.23)| 22(30.99)|        | 16(21.05) |            |     |           |           |      |                 |       |      |      |           |           |     |        |        |     |        |        |     |        |        |
| <40U/L         | 89(71.77)| 49(69.01)|        | 60(78.95) |            |     |           |           |      |                 |       |      |      |           |           |     |        |        |     |        |        |     |        |        |
| AST            |         |         | 0.633   |           |           |     |           |           |      |                 |       |      |      |           |           |     |        |        |     |        |        |     |        |        |
| ≥40U/L         | 41(33.06)| 19(26.76)|        | 25(32.89) |            |     |           |           |      |                 |       |      |      |           |           |     |        |        |     |        |        |     |        |        |
| <40U/L         | 83(66.94)| 52(73.24)|        | 51(67.11) |            |     |           |           |      |                 |       |      |      |           |           |     |        |        |     |        |        |     |        |        |
| LDH            |         |         | 0.341   |           |           |     |           |           |      |                 |       |      |      |           |           |     |        |        |     |        |        |     |        |        |
| ≥245U/L        | 36(29.03)| 26(36.62)|        | 29(38.16) |            |     |           |           |      |                 |       |      |      |           |           |     |        |        |     |        |        |     |        |        |
| <245U/L        | 88(70.97)| 45(63.38)|        | 47(61.84) |            |     |           |           |      |                 |       |      |      |           |           |     |        |        |     |        |        |     |        |        |
| γ-GT           |         |         | 0.262   |           |           |     |           |           |      |                 |       |      |      |           |           |     |        |        |     |        |        |     |        |        |
| ≥50U/L         | 64(51.61)| 28(39.44)|        | 36(47.37) |            |     |           |           |      |                 |       |      |      |           |           |     |        |        |     |        |        |     |        |        |
| <50U/L         | 60(48.39)| 43(60.56)|        | 40(52.63) |            |     |           |           |      |                 |       |      |      |           |           |     |        |        |     |        |        |     |        |        |
| Cre                | 0.303 |
|--------------------|-------|
| >80umol/L          | 41(33.06) | 29(40.85) | 21(27.63) |
| ≤80umol/L          | 83(66.94) | 42(59.15) | 55(72.37) |
| Outcomes           | 0.070 |
| Dead               | 22(17.74) | 22(30.99) | 14(18.42) |
| Alive              | 102(82.26) | 49(69.01) | 62(81.58) |

Abbreviations: WBC, white blood cell; PLT, platelet; CRP, C-reactive protein; PCT: procalcitonin; IL-6, interleukin-6; SaO2, Oxygen saturation; TBIL, total bilirubin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; LDH, lactate dehydrogenase; γ-GT, γ-glutamyl transpeptidase; Cre, creatinine.

Table 2. Baseline characteristics of patients in the training cohort
| Variables                          | Death (N=22) | Discharge (N=102) | P     |
|-----------------------------------|--------------|-------------------|-------|
| Age, years (Mean±SD)              | 81.55±7.31   | 70.39±12.27       | <0.001|
| Gender                            |              |                   |       |
| Male                              | 14 (63.64)   | 55 (53.92)        | 0.407 |
| Comorbidity                       |              |                   | 0.005 |
| Without comorbidity               | 1 (4.55)     | 30 (29.41)        |       |
| With single comorbidity           | 6 (27.27)    | 32 (31.37)        |       |
| With multiple comorbidity         | 15 (68.18)   | 40 (39.22)        |       |
| smoke                             | 13 (59.09)   | 53 (51.96)        | 0.545 |
| Panting (breathing rate ≥30/min)  | 17 (77.27)   | 39 (38.24)        | 0.001 |
| WBC                               |              |                   | 0.001 |
| >10*10^9/L                        | 10 (45.45)   | 14 (13.73)        |       |
| ≤10*10^9/L                        | 12 (54.55)   | 88 (86.27)        |       |
| Lymphocyte                        |              |                   | <0.001|
| >1.0*10^9/L                       | 2 (9.09)     | 54 (52.94)        |       |
| ≤1.0*10^9/L                       | 20 (90.91)   | 48 (47.06)        |       |
| Neutrophil                        |              |                   | 0.001 |
| >6.3*10^9/L                       | 13 (59.09)   | 23 (22.55)        |       |
| ≤6.3*10^9/L                       | 9 (40.91)    | 79 (77.45)        |       |
| PLT                               |              |                   | 0.076 |
| ≥100*10^9/L                       | 18 (81.82)   | 96 (94.12)        |       |
| <100*10^9/L                       | 4 (18.18)    | 6 (5.82)          |       |
| CRP                               |              |                   | 0.008 |
| >10 mg/L                          | 18 (81.82)   | 52 (50.98)        |       |
| ≤10 mg/L                          | 4 (18.18)    | 50 (49.02)        |       |
| D-dimer                           |              |                   | 0.006 |
| >0.55 mg/L                        | 20 (90.91)   | 61 (59.80)        |       |
| Parameter          | Value 1 | Value 2 |
|-------------------|---------|---------|
| ≤0.55mg/L         | 2(9.09) | 41(40.20) |
| PCT               | 0.020   |         |
| >0.05ng/mL        | 20(90.91) | 67(65.68) |
| ≤0.05ng/mL        | 2(9.09) | 35(34.32) |
| IL-6              | <0.001  |         |
| ≥10pg/mL          | 21(95.45) | 47(46.08) |
| <10pg/mL          | 1(4.55)  | 55(53.92) |
| SaO\textsubscript{2} on admission | 0.294 |         |
| ≥90\%             | 13(59.09) | 72(70.59) |
| <90\%             | 9(40.91)  | 30(29.41) |
| TBIL              | 0.326   |         |
| ≥20umol/L         | 10(45.45) | 35(34.31) |
| <20umol/L         | 12(54.55) | 67(65.69) |
| ALT               | 0.147   |         |
| ≥40U/L            | 9(40.91)  | 26(25.49) |
| <40U/L            | 13(59.09) | 76(74.51) |
| AST               | 0.213   |         |
| ≥40U/L            | 10(45.45) | 31(30.39) |
| <40U/L            | 12(54.55) | 71(69.61) |
| LDH               | 0.352   |         |
| ≥245U/L           | 14(63.64) | 75(73.53) |
| <245U/L           | 8(36.36)  | 27(26.47) |
| γ-GT              | 0.441   |         |
| ≥50U/L            | 13(59.09) | 51(50.00) |
| <50U/L            | 9(40.91)  | 51(50.00) |
| Cre               | 0.718   |         |
| >80umol/L         | 8(36.36)  | 33(32.35) |
| ≤80umol/L         | 14(63.64) | 69(67.65) |

Abbreviations: WBC, white blood cell; PLT, platelet; CRP, C-reactive protein; PCT: procalcitonin; IL-6, interleukin-6; SaO\textsubscript{2}, Oxygen saturation; TBIL, total bilirubin; ALT, alanine aminotransferase; AST,
aspartate aminotransferase; LDH, lactate dehydrogenase; γ-GT, γ-glutamyl transpeptidase; Cre, creatinine.

Table 3. Univariate and Multivariate Cox Proportional Hazards Regression Analysis of death in the Training Cohort
| Variable                              | Univariate          |         |         |         |         |
|--------------------------------------|---------------------|---------|---------|---------|---------|
|                                      | HR (95% CI)         | P       | HR (95% CI) | P       |         |
| Age(≥70 vs <70)                      | 9.245(2.054-11.624) | 0.004   | 1.184(1.061-1.321) | 0.003   |         |
| Gender(Male vs Female)               | 1.495(0.577-3.874)  | 0.407   | -        | -       |         |
| Comorbidity                          | -                   | -       | -        | -       |         |
| Without comorbidity                  | 1                   | 1       | 1        | 1       |         |
| With single comorbidity              | 3.625(0.639-4.503)  | 0.120   | 1.810(0.794-2.585) | 0.551   |         |
| With multiple comorbidity            | 2.250(1.407-4.947)  | 0.022   | 1.155(0.831-3.130) | 0.479   |         |
| Smoke(Yes vs No)                     | 1.309(0.533-3.212)  | 0.556   | -        | -       |         |
| Panting(breathing rate ≥30/min)(Yes vs No) | 5.492(2.876-7.078)  | 0.002   | 3.300(2.509-6.286) | 0.004   |         |
| WBC(>10*10^9/L vs ≤10*10^9/L)        | 5.238(1.906-9.397)  | 0.001   | 2.046(0.726-4.503) | 0.524   |         |
| Lymphocyte(<1.0*10^9/L vs ≥1.0*10^9/L) | 5.263(2.513-9.615)  | 0.002   | 2.283(1.779-3.267) | 0.011   |         |
| Neutrophil(>6.3*10^9/L vs ≤6.3*10^9/L) | 4.961(1.884-8.068)  | 0.001   | 2.439(0.717-3.768) | 0.392   |         |
| PLT(≥100*10^9/L vs <100*10^9/L)      | 3.556(0.911-6.876)  | 0.068   | -        | -       |         |
| CRP(>10mg/L vs ≤10mg/L)              | 4.327(1.369-7.677)  | 0.013   | 1.214(0.721-2.211) | 0.196   |         |
| D-dimer(>0.55mg/L vs ≤0.55mg/L)      | 6.721(1.490-9.319)  | 0.013   | 1.395(0.668-3.268) | 0.195   |         |
| PCT(>0.05ng/mL vs ≤0.05ng/mL)        | 3.224(1.154-6.645)  | 0.032   | 2.255(0.768-4.767) | 0.118   |         |
| IL-6(>10pg/mL vs ≤10pg/mL)           | 4.547(3.184-8.659)  | 0.002   | 3.029(1.567-7.116) | 0.009   |         |
| SaO₂ on admission(≥90% vs <90%)      | 1.662(0.739-2.007)  | 0.180   | -        | -       |         |
| TBIL(≥20umol/L vs <20umol/L)         | 1.595(0.627-2.057)  | 0.327   | -        | -       |         |
| ALT(≥40U/L vs <40U/L)                | 2.024(0.775-5.283)  | 0.150   | -        | -       |         |
| Test                  | Hazard Ratio (95% CI) | P-value | 95% CI | HR | 95% CI |
|-----------------------|-----------------------|---------|-------|----|--------|
| AST (≥40U/L vs <40U/L) | 1.909 (0.746-4.883)   | 0.177   | -     | -  | -      |
| LDH (≥245U/L vs <245U/L) | 1.923 (0.739-5.007)   | 0.180   | -     | -  | -      |
| γ-GT (≥50U/L vs <50U/L) | 1.444 (0.567-3.677)   | 0.440   | -     | -  | -      |
| Cre (>80umol/L vs ≤80umol/L) | 1.195 (0.456-3.129)   | 0.717   | -     | -  | -      |

Abbreviations: WBC, white blood cell; PLT, platelet; CRP, C-reactive protein; PCT: procalcitonin; IL-6, interleukin-6; SaO2, Oxygen saturation; TBIL, total bilirubin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; LDH, lactate dehydrogenase; γ-GT, γ-glutamyl transpeptidase; Cre, creatinine; HR, hazard ratio; 95% CI, 95% Confidence interval.